Semaglutide vs Retatrutide

Overview

Semaglutide and Retatrutide represent two generations of incretin-based peptide therapeutics for metabolic research. Semaglutide, the established GLP-1 receptor agonist approved by Health Canada under the brands Ozempic® and Wegovy®, revolutionised weight management with clinical trial weight reductions of approximately 15–17%. Retatrutide, developed by Eli Lilly, pushes the frontier further by simultaneously targeting three receptors — GIP, GLP-1, and glucagon — achieving weight reductions of up to 28.7% in Phase 3 trials.

This comparison examines the fundamental differences in their mechanisms, the strength of their clinical evidence, and what the emergence of triple agonists means for the future of metabolic peptide research. For Canadian researchers, the distinction between an approved pharmaceutical and an investigational compound under corporate development is critical context.

Quick Comparison Table

Mechanism of Action: Single vs Triple Agonism

Semaglutide: The GLP-1 Specialist

Semaglutide is a GLP-1 receptor agonist with 94% structural homology to the natural human GLP-1 hormone. It targets a single receptor to achieve its metabolic effects through three primary pathways: appetite suppression via hypothalamic GLP-1 receptors, delayed gastric emptying in the gut, and glucose-dependent insulin secretion from pancreatic beta cells. Its structural modifications — an amino acid substitution at position 8 and a C18 fatty diacid chain — protect it from enzymatic degradation and extend its half-life to approximately one week.

Retatrutide: The Triple Threat

Retatrutide activates all three incretin and metabolic receptors simultaneously, with a carefully calibrated potency profile. Its GIP receptor activation is the strongest (8.9x endogenous potency), followed by moderate GLP-1 activation (0.4x) and modest glucagon receptor activation (0.3x). The crucial innovation is the glucagon receptor component — while GLP-1 and GIP primarily reduce caloric intake, glucagon receptor agonism increases energy expenditure through enhanced thermogenesis and hepatic fat oxidation. This means Retatrutide addresses both sides of the energy balance equation simultaneously.

Clinical Evidence: Depth vs Magnitude

Semaglutide: Decades of Data

Semaglutide benefits from one of the most comprehensive clinical trial programmes in metabolic medicine:

• STEP 1: 16.9% mean body weight reduction over 68 weeks versus 2.4% for placebo
• STEP 2: 9.6% weight loss in patients with type 2 diabetes
• SELECT trial: 20% reduction in major adverse cardiovascular events
• Tens of thousands of trial participants across multiple indications
• Real-world prescribing data from millions of patients globally

The depth and breadth of Semaglutide's evidence base is unmatched by any other weight management compound.

Retatrutide: Record-Breaking Early Data

While still early in development, Retatrutide's clinical results have been remarkable:

• Phase 2 (48 weeks): Up to 24.2% mean weight reduction — participants had not reached a plateau
• TRIUMPH-4 Phase 3 (68 weeks): Up to 28.7% mean weight reduction (approximately 71 lbs)
• 58.6% of participants on the 12 mg dose achieved ≥25% weight loss
• 39.4% achieved ≥30% weight loss
• Dramatic liver fat reductions: 42.9% to 82.4% at 24 weeks across doses

However, the evidence base is still maturing. Phase 3 results from seven TRIUMPH trials are expected in 2026, which will provide the comprehensive dataset needed for regulatory submissions.

Safety Profiles

Both compounds share a similar gastrointestinal side-effect profile — nausea, diarrhoea, constipation, and vomiting are the most common adverse events, occurring during dose escalation and generally improving over time.

Semaglutide carries a boxed warning for medullary thyroid carcinoma (based on rodent studies), known risks for pancreatitis and gallbladder disease, and well-characterised long-term safety from years of clinical and real-world use.

Retatrutide has a unique side effect not observed with Semaglutide: dysaesthesia (altered skin sensation), reported in 9–21% of patients. Discontinuation rates were higher than placebo (12–18% vs 4%), with some patients discontinuing due to perceived excessive weight loss. Long-term safety data is still being gathered through ongoing trials.

Canadian Context

Semaglutide is available by prescription in Canada as Ozempic® (type 2 diabetes), Wegovy® (weight management), and Rybelsus® (oral, type 2 diabetes). Supply shortages have been a recurring issue since 2023. Provincial formulary coverage varies — some provinces cover Ozempic for diabetes but not Wegovy for weight management. For background on the regulatory landscape for peptides in Canada, see our dedicated guide.

Retatrutide is not available in Canada outside of clinical trials. Unlike research peptides such as BPC-157 or TB-500, which can be obtained from research chemical suppliers, Retatrutide is a pharmaceutical-grade compound under active corporate development by Eli Lilly. If Phase 3 trials succeed and regulatory submissions are approved, Retatrutide would become a prescription medication — following the same path Semaglutide took.

The Bigger Picture: Evolution of Metabolic Peptides

The progression from Semaglutide to Retatrutide illustrates the rapid evolution of metabolic peptide research:

• Generation 1 — Single agonists: Semaglutide (GLP-1 only) — ~15–17% weight loss
• Generation 2 — Dual agonists: Tirzepatide (GIP + GLP-1) — ~20–22% weight loss
• Generation 3 — Triple agonists: Retatrutide (GIP + GLP-1 + Glucagon) — up to ~29% weight loss

Each generation adds a new receptor target, and the clinical data suggests that each addition provides meaningful incremental benefit. For researchers studying metabolic pathways, this progression offers compelling evidence that multi-receptor approaches may be the future of metabolic therapeutics.

Bottom Line for Researchers

• Studying approved GLP-1 therapeutics? Semaglutide remains the gold standard with the deepest evidence base and real-world prescribing data.
• Investigating multi-receptor metabolic modulation? Retatrutide represents the cutting edge of triple agonist research.
• Comparing weight loss efficacy? Cross-study comparisons favour Retatrutide, but head-to-head trials have not been conducted.
• Interested in liver fat research? Retatrutide's dramatic liver fat reductions make it particularly notable for MASLD/NAFLD research.
• Need a comparator for metabolic research? Understanding both compounds is essential for contextualising any modern weight management research.